Frontline Regimens Explored for EGFR-Mutated NSCLC
December 20th 2020During a Targeted Oncology Case Based Peer Perspective event, John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center, discusses the case of a 73-year-old Asian patients with EGFR-mutant non–small cell lung cancer.
Comparing Immunochemotherapy Combinations in Patients With ES-SCLC
December 19th 2020Jun Zhang, MD, PhD, associate professor, University of Kansas Medical Center, reviews the preferred treatment options for extensive-stage small cell lung cancer in a 73-year-old patient during a Targeted Oncology Case Based Peer Perspective event.
Different Staging, Risk Stratification, and Treatment Methods for Acute GVHD
December 17th 2020During a Targeted Oncology Case Based Peer Perspectives event, Miguel-Angel Perales, MD, discussed testing for risk stratification and treatment of graft-versus-host-disease based on the case of a 48-year-old man.
Trials Demonstrate Which Treatments Physicians Should Use in EGFR+ NSCLC
December 14th 2020Edgardo S. Santos Castillero, MD, reviewed the case of a 73-year-old Asian man who was diagnosed with stage IV EGFR-mutant non-small cell lung cancer and discussed the treatment options he would consider for this patient.
Multiple Studies Provide Efficacy Results for Lenvatinib in Thyroid Cancer
November 27th 2020Matthew Taylor, MD, reviewed the clinical trials supporting levantinib as a treatment option for a patient with thyroid cancer and discussed the option with a group of oncologists during a Targeted Oncology Case Base Peer Perspectives event.
In Patients With Relapsed/Refractory DLBCL, Tafasitamab/Lenalidomide Combo Shines
November 26th 2020Kami J. Maddocks, MD, discussed the efficacy and safety of tafasitamab in combination with lenalidomide as treatment of a 74-year-old man with diffuse large B-cell lymphoma. The treatment option was discussed with a group of oncologists during a Targeted Oncology Case Based Peer Perspective event.
Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid Cancer
November 25th 2020During a Targeted Oncology Case Based Peer Perspectives event, Marcia S. Brose, MD, PhD, discussed options for a 58-year-old patient with RET-mutant medullary thyroid cancer.
Morgans Discusses Therapy Options for Metastatic and Nonmetatstatic CRPC
November 24th 2020During a Targeted Oncology Case Based Peer Perspectives event, Alicia K. Morgans, MD, MPH, reviewed 2 cases of patients with nonmetastatic castration resistant prostate cancer and explained the potential testing and treatment options.